Allarity Therapeutics, Inc.
About Allarity Therapeutics, Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$11.2M
- Total assets
- $18.3M
- Market cap
- $25.6M
- Operating margin
- -3939.1%
- Net margin
- -3509.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $320.0K
- Operating expenses
- $12.9M
- Operating income
- -$12.6M
- Income tax
- $0
- Net income
- -$11.2M
- EPS (basic)
- $-0.78
Balance sheet
- Total assets
- $18.3M
- Current assets
- $17.9M
- Total liabilities
- $8.4M
- Current liabilities
- $8.4M
- Shareholders’ equity
- $9.8M
Cash flow
- Operating cash flow
- -$14.8M
- Investing cash flow
- -$8.0K
- Financing cash flow
- $10.6M
- Net cash flow
- -$4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $25.6M
- Shares outstanding
- 16.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 21, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.2M.
- Revenue grew 124% from FY2021 to FY2025.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Allarity Therapeutics, Inc..
Write a review
News about Allarity Therapeutics, Inc.
News & sentiment via Polygon.io
